In patients with Parkinson’s disease and similar conditions, L-Dopa
may be the most effective drug to address dopamine deficiencies. However, L-Dopa loses this effectiveness over time. A team of researchers posit that continued neuron death leaves the dopamine created by L-Dopa with fewer receptors to which it can bind. These researchers are working to understand the problem, and ultimately, keep L-Dopa working longer.